Status:

COMPLETED

Research Aimed at Improving Both Mood and Weight

Lead Sponsor:

Palo Alto Medical Foundation

Collaborating Sponsors:

National Heart, Lung, and Blood Institute (NHLBI)

University of Washington

Conditions:

Depression

Obesity

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The RAINBOW study is an NIH R01-funded randomized controlled trial to evaluate the clinical and cost effectiveness and implementation potential of a primary care integrated multicondition intervention...

Detailed Description

The large numbers of primary care patients affected by coexisting obesity and depression and common risk factors for diabetes and heart disease underscore the urgency of developing effective, accessib...

Eligibility Criteria

Inclusion

  • RAINBOW
  • Inclusion criteria:
  • Ethnicity and race: Any;
  • Obesity: BMI≥30 kg/m2 for non-Asians; BMI≥27 kg/m2 for Asians;
  • Clinically significant depressive symptoms: PHQ-9≥10;
  • A PAMF patient for ≥1 year
  • Seen in primary care at least once in the preceding 24 months;
  • Able and willing to enroll and meet the requirements of the study
  • Exclusion criteria:
  • Inability to speak, read or understand English;
  • Having no reliable telephone service, no device to use to watch a DVD, or no regular Internet access via a computer and/or mobile device;
  • Had bariatric surgery within the past 12 months or plans to undergo bariatric surgery during the 24-month study period;
  • Ongoing psychiatric care outside of the PAMF network.
  • Active suicidal ideation that includes active plan and/or intent;
  • Any Axis I disorder other than Minor or Major Depressive Disorder and/or Dysthymia, with the exception of any comorbid Anxiety Disorder;
  • Active Bulimia Nervosa within the past 12 months (however Binge Eating Disorder without purging is not an exclusionary condition);
  • Active alcohol or substance use disorder (including prescription drugs).
  • Pre-existing diabetes (other than during pregnancy) or diabetes diagnosed as a result of fasting blood glucose or hemoglobin A1c levels obtained through study screening;
  • Pre-existing cardiovascular disease.
  • Diagnosis of cancer (other than non-melanoma skin cancer) that is/was active or treated with radiation or chemotherapy within the past 12 months;
  • Severe medical comorbidities that require aggressive treatment, e.g., stage 4 or greater renal disease, liver failure;
  • Diagnosis of a terminal illness and/or in hospice care;
  • Residence in long-term care facility;
  • Cognitive impairment based on the Callahan 6-item scale
  • Plan to move out of the area or transfer care outside PAMF during the study period;
  • Investigator discretion for reasons of clinical safety or protocol adherence.
  • ENGAGE
  • Inclusion criteria:
  • • RAINBOW participant
  • Exclusion criteria:
  • Weight over 350 pounds
  • MRI is contraindicated
  • Traumatic brain injury

Exclusion

    Key Trial Info

    Start Date :

    September 30 2014

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    December 21 2018

    Estimated Enrollment :

    409 Patients enrolled

    Trial Details

    Trial ID

    NCT02246413

    Start Date

    September 30 2014

    End Date

    December 21 2018

    Last Update

    April 26 2024

    Active Locations (2)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (2 locations)

    1

    Palo Alto Medical Foundation

    Palo Alto, California, United States, 94301

    2

    Stanford University

    Stanford, California, United States, 94305